DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Urruticoechea A, Rizwanullah M, Im SA. et al.
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.
J Clin Oncol 2018;
36 (Suppl.) Abstr.. 1013
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.